Cell-Penetrating Peptide Nanovesicles Target the Endoplasmic Reticulum Inside Cells | Research

The takeaway

Penetratin-conjugated lipid/polymer hybrid nanovesicles achieved specific endoplasmic reticulum targeting with effective lysosomal escape, enabling intracellular drug delivery to the ER for diseases linked to ER stress.

Subcellular ER targeting
CPP-nanovesicles reached the specific organelle (ER) inside cells — not just entering cells but navigating to the correct subcellular destination

What the researchers found

Penetratin-conjugated LPNVs showed efficient cellular uptake, specific ER-targeting, and remarkable lysosomal escape due to pH buffering by PEO-b-PCL-b-PEO, enabling intracellular ER-targeted delivery.

Why it matters

ER dysfunction drives many diseases but has been difficult to target therapeutically. A delivery system that specifically reaches the ER inside cells could enable a new class of subcellular precision medicines.

The numbers in context

9% lysosomal co-localization for CPP-coated nanovesicles vs. higher rates for controls

How the study worked

In vitro study. Lipid/polymer hybrid nanovesicles (PEO-b-PCL-b-PEO + DPPC) conjugated with Penetratin CPP. Cellular uptake, ER co-localization, lysosomal escape, and comparison with other CPP-conjugated LPNVs assessed.

Who was studied

Cultured human cells

What this study cannot tell us

In vitro cell culture study. No disease model testing. ER-targeting specificity in vivo unknown. Drug loading and therapeutic efficacy not demonstrated. Nanoparticle manufacturing scalability not addressed.

How to read the evidence

Low evidence grade: in vitro proof-of-concept for ER-targeted delivery without disease model or therapeutic testing.

When this study was published

Published 2021. Organelle-targeted drug delivery is an emerging field with growing pharmaceutical interest.

The bigger picture

Subcellular targeting represents the next frontier in drug delivery — going beyond just getting drugs into cells to delivering them to specific organelles. CPP-nanovesicle platforms make this possible for the first time.

Questions still open

Can ER-targeted nanovesicles deliver therapeutic agents that correct ER stress in disease models?
How does ER targeting change the efficacy of drugs for neurodegenerative conditions?
Would this system work in vivo with similar ER-targeting specificity?

Common questions

What is the endoplasmic reticulum and why target it?

The ER is a cell structure that processes proteins and handles calcium storage. When it malfunctions (ER stress), it contributes to neurodegeneration, inflammation, and other diseases. Targeting drugs directly to the ER could treat these conditions more effectively.

How does the delivery system escape lysosomal destruction?

The polymer component (PEO-b-PCL-b-PEO) acts as a pH buffer inside lysosomes, causing them to swell and release the nanovesicles before the contents are destroyed. This "lysosomal escape" is critical for getting the drug to its target.

Read the original research

Cell-penetrating peptide-conjugated lipid/polymer hybrid nanovesicles for endoplasmic reticulum-targeting intracellular delivery.

Journal of materials chemistry. B, 9(2), 464-470

View on PubMed ↗Publisher’s paper ↗

Citation

Kang, Jeong Yi; Kim, Seulgi; Kim, Juhyeon; Kang, Nae-Gyu; Yang, Chul-Su; Min, Sun-Joon; Kim, Jin Woong. (2021). Cell-penetrating peptide-conjugated lipid/polymer hybrid nanovesicles for endoplasmic reticulum-targeting intracellular delivery.. Journal of materials chemistry. B, 9(2), 464-470. https://doi.org/10.1039/d0tb01940b